Translatability scoring in prospective and retrospective COVID drug development cases.

ABSTRACT:

Background

The ongoing pandemic of severe acute respiratory syndrome coronavirus 2 has led to an enormous surge of clinical research. So far, the speed and success rate of related drug development projects, especially of vaccines, is unprecedented. For the first time, this situation allowed for the opportunistic evaluation of a translatability score, originally proposed in 2009, in a prospective manner.

Methods

Several vaccines and treatments under development in clinical phase III trials were selected for translational scoring with the translatability score. Six prospective and six retrospective case studies were performed. The scores had to be determined for a fictive date before any results of the phase III trial were reported in any media. Spearman correlation analysis a

SUBMITTER: Wendler A 

PROVIDER: S-EPMC10243273 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature